Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ReShape Lifesciences, Inc. - Common Stock (NQ:RSLS)

4.180 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ReShape Lifesciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys Progress Towards Completion 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
Effective as of Commencement of Trading on May 9, 2025 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
Patent Expands and Strengthens Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
ReShape Enters Exclusive U.S. Distribution Agreement in the Neuromuscular Rehabilitation Market 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Power Nickel (TSX.V: PNPN) – Undervalued Precious, Battery, Energy and Base Metals Play Amidst Gold Surge – More Stocks Inside
Via AB Newswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
From Kahn Swick & Foti, LLC
Via Business Wire
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Route to Treat Type 2 Diabetes and Hypoglycemia 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
Liaison Medical is Among the Largest Surgical Device Distributors in Canada 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
Vagal Neuromodulation Provides Path to Treat Type 2 Diabetes and Hypoglycemia 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Transactions Continue to Progress and Remain on Track 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, November 14, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
FLEX Technology Designed to Improve the Patient Experience 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes
Approximately $241,000 Grant Will Be Utilized to Conduct Minimally Invasive Laparoscopic Surgical Electrode Implantation Techniques and Long Duration Safety and Blood Glucose Modulation Experiments for... 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
Effective as of Commencement of Trading on September 23, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Thursday, August 15, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHUY, RSLS on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS
From Kahn Swick & Foti, LLC
Via Business Wire
RSLS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of ReShape Lifesciences Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
Conference Call to be Held at 4:30 pm ET on Wednesday, May 15, 2024 
From ReShape Lifesciences Inc
Via GlobeNewswire
ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.